A
Anja Feldmann
Researcher at Max Planck Society
Publications - 368
Citations - 18932
Anja Feldmann is an academic researcher from Max Planck Society. The author has contributed to research in topics: The Internet & Antigen. The author has an hindex of 67, co-authored 340 publications receiving 17422 citations. Previous affiliations of Anja Feldmann include Saarland University & AT&T.
Papers
More filters
Posted Content
Online Strategies for Intra and Inter Provider Service Migration in Virtual Networks
TL;DR: Both randomized and deterministic, gravity center based online algorithms are presented which achieve a good tradeoff between improved QoS and migration cost in the worst-case, both for service migration within an infrastructure provider as well as for networks supporting cross-provider migration.
Proceedings ArticleDOI
Stellar: network attack mitigation using advanced blackholing
TL;DR: It is shown that fine-grained blackholing can be realized, e.g., at a major IXP, by combining available hardware filters with novel signaling mechanisms and Stellar reduces the required level of cooperation to enhance mitigation effectiveness.
Journal ArticleDOI
Improving Content Delivery with PaDIS
TL;DR: The authors propose and deploy the Provider-aided Distance Information System (PaDIS), which lets ISPs augment the CDN server by utilizing their unique knowledge about network conditions and user locations.
Proceedings ArticleDOI
BGP Communities: Even more Worms in the Routing Can
Florian Streibelt,Franziska Lichtblau,Robert Beverly,Anja Feldmann,Cristel Pelsser,Georgios Smaragdakis,Randy Bush +6 more
TL;DR: BGP communities are a mechanism widely used by operators to manage policy, mitigate attacks, and engineer traffic; e.g., to drop unwanted traffic, filter announcements, adjust local preference, and prepend paths to influence peer selection but can be exploited by remote parties to influence routing in unintended ways.
Journal ArticleDOI
Conventional CARs versus modular CARs
Anja Feldmann,Claudia Arndt,Stefanie Koristka,Nicole Berndt,Nicole Berndt,Ralf Bergmann,Michael Bachmann +6 more
TL;DR: The development of a modular CAR variant termed universal CAR (UniCAR) system that promises to overcome limitations of conventional CARs and targeting of tumor-associated antigens that are not only expressed on tumor cells but also on vital tissues is summarized.